Cutaneous Melanoma Clinical Trial
Official title:
Lower Limb Cutaneous Melanoma: Observational Prognostic Study About Specific Location of the Primary Lesion.
Observational study to know the relevance of specific anatomical location of cutaneous melanoma on lower limbs.
| Status | Recruiting |
| Enrollment | 300 |
| Est. completion date | December 2021 |
| Est. primary completion date | December 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: - Cutaneous melanoma on the lower limb Exclusion Criteria: - Incomplete staging |
| Country | Name | City | State |
|---|---|---|---|
| Spain | Hospital Universitario "Virgen de la Arrixaca" | Murcia |
| Lead Sponsor | Collaborator |
|---|---|
| Hospital Universitario Virgen de la Arrixaca |
Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Melanoma-specific overall survival | Melanoma-specific overall survival | Ten years | |
| Primary | Melanoma-specific disease-free survival | Melanoma-specific disease-free survival | Ten years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
| Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04020809 -
Neoadjuvant Atezolizumab in Cutaneous Melanoma
|
Phase 1 | |
| Completed |
NCT03620019 -
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
|
Phase 2 | |
| Recruiting |
NCT03767348 -
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
|
Phase 2 | |
| Completed |
NCT03628417 -
Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases
|
N/A | |
| Withdrawn |
NCT05482074 -
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
|
Phase 2 | |
| Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT04551352 -
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
|
Phase 1 | |
| Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT05628883 -
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
|
Phase 1 | |
| Terminated |
NCT04254107 -
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT04830124 -
Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
|
Phase 2 | |
| Recruiting |
NCT03699995 -
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
|
N/A | |
| Recruiting |
NCT06319196 -
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
|
Phase 2 | |
| Recruiting |
NCT05253872 -
The MELAcare Study: A New Method for Surveillance of Melanoma Patients
|
N/A | |
| Recruiting |
NCT04706962 -
TH1902 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04792463 -
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
|
||
| Completed |
NCT00679289 -
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
|
Phase 2 | |
| Recruiting |
NCT05669430 -
A Study of GV20-0251 in Patients With Solid Tumor Malignancies
|
Phase 1 |